Last reviewed · How we verify

NCT03807128: MYRACLE

MYeloma Resistance And Clonal Evolution

Recruiting now Last updated 14 July 2025
What this trial tests

trial testing Prélèvement sanguin (2*4mL) ou médullaire (2mL) in Multiple Myeloma in 1,400 participants. Currently enrolling.

Timeline
11 February 2019
Primary endpoint
11 February 2034
11 February 2049

Quick facts

Lead sponsorNantes University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,400
Start date11 February 2019
Primary completion11 February 2034
Estimated completion11 February 2049
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.
    Derrien J, Gastineau S, Frigout A, Giordano N, et al · · 2023 · cited 56× · PMID 37653140 · DOI 10.1038/s43018-023-00625-9
  2. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C, Maiga S, Touzeau C, Bellanger C, et al · · 2020 · cited 36× · PMID 32371863 · DOI 10.1038/s41419-020-2505-1
  3. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
    Carretero-Iglesia L, Hall OJ, Berret J, Pais D, et al · · 2024 · cited 25× · PMID 39261676 · DOI 10.1038/s43018-024-00821-1
  4. Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.
    Grandclément C, Estoppey C, Dheilly E, Panagopoulou M, et al · · 2024 · cited 15× · PMID 38448430 · DOI 10.1038/s41467-024-46310-y
  5. Targeting Oxidative Stress With Auranofin or Prima-1<sup>Met</sup> to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.
    Tessoulin B, Descamps G, Dousset C, Amiot M, et al · · 2019 · cited 15× · PMID 30895171 · DOI 10.3389/fonc.2019.00128
  6. VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target.
    Champion O, Maïga S, Antier C, Dousset C, et al · · 2025 · cited 2× · PMID 39915649 · DOI 10.1038/s41375-025-02523-8
  7. Targeting BCMA in multiple myeloma with a trifunctional NK cell engager
    Tang A, Gauthier L, Zaghi E, Beninga J, et al · · 2026

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03807128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing